- Home
- ENTX vs IGMS Comparison
ENTX vs IGMS Comparison
Compare ENTX & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- IGMS
- Stock Information
- Founded
- ENTX 2010
- IGMS 1993
- Country
- ENTX Israel
- IGMS United States
- Employees
- ENTX N/A
- IGMS N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- IGMS Health Care
- Exchange
- ENTX Nasdaq
- IGMS Nasdaq
- Market Cap
- ENTX 69.6M
- IGMS 82.1M
- IPO Year
- ENTX 2018
- IGMS 2019
- Fundamental
- Price
- ENTX $1.79
- IGMS $1.22
- Analyst Decision
- ENTX Strong Buy
- IGMS Hold
- Analyst Count
- ENTX 1
- IGMS 8
- Target Price
- ENTX $10.00
- IGMS $6.14
- AVG Volume (30 Days)
- ENTX 30.9K
- IGMS 167.6K
- Earning Date
- ENTX 05-09-2025
- IGMS 05-07-2025
- Dividend Yield
- ENTX N/A
- IGMS N/A
- EPS Growth
- ENTX N/A
- IGMS N/A
- EPS
- ENTX N/A
- IGMS N/A
- Revenue
- ENTX $181,000.00
- IGMS $2,679,000.00
- Revenue This Year
- ENTX N/A
- IGMS $121.76
- Revenue Next Year
- ENTX N/A
- IGMS $46.83
- P/E Ratio
- ENTX N/A
- IGMS N/A
- Revenue Growth
- ENTX N/A
- IGMS 25.77
- 52 Week Low
- ENTX $1.41
- IGMS $0.92
- 52 Week High
- ENTX $2.79
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ENTX 49.59
- IGMS 47.65
- Support Level
- ENTX $1.50
- IGMS $1.16
- Resistance Level
- ENTX $1.84
- IGMS $1.31
- Average True Range (ATR)
- ENTX 0.11
- IGMS 0.12
- MACD
- ENTX 0.03
- IGMS 0.03
- Stochastic Oscillator
- ENTX 85.50
- IGMS 76.92
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.